On April 30, 2026 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, reported its financial results for the fiscal year ending December 31, 2025. The Annual Report 2025, as approved by the management and supervisory boards on April 30, 2025, is available on TME Pharma’s website (www.tmepharma.com).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In June 2025, TME Pharma changed its organizational structure to a virtual company structure to allow it to continue pursuing the goals of financing, licensing or M&A transactions focused on its clinical stage assets, NOX-A12 and NOX-E36 while minimizing costs by outsourcing essentially all functions to maintain the programs and conduct industrial partner and investor outreach.
2025 Financial Summary
On December 31, 2025, TME Pharma and its subsidiaries had cash resources of €2 million. In March 2026, TME announced that it had agreed with certain lenders, involved in the May 2025 and August 2025 financing, to extend the maturity of their loans by a further 12 months, extending the cash runway into Q2 2027 taking into consideration the current level of business operations.
As in prior years, TME Pharma has not generated any revenues. The Group – TME Pharma N.V.,TME Pharma AG – does not expect to generate any revenues from any product candidates that it develops until the Group either signs a licensing agreement or obtains regulatory approval and commercializes its products or enters into collaborative agreements with third parties.
The Net loss in 2025 amounted €3.3M (2024: €5.7M). Total equity as of December 31, 2025 is now €1.6M negative (December 31, 2024: €1.6M positive).
Outlook for 2026
At this time, TME Pharma is focusing on securing licensing agreements or partnerships for NOX-A12 and NOX-E36.
As announced in 2025, the company is also exploring alternative sources of revenue and activities as well as financing and partnering solutions for NOX-A12 and NOX-E36. TME Pharma will seek shareholder approval as required for any potential transactions which emerge as part of the new strategy and issue press releases on all material developments.
Diede van den Ouden, CEO of TME Pharma, said: "As a shareholder and as a director, I remain optimistic about the future of TME Pharma. Publications, like in *Nature Communications* on triple therapy for NOX-A12, demonstrates that TME assets could hold significant potential value. It is up to us to realize that value."
(Press release, TME Pharma, APR 30, 2026, View Source [SID1234664993])